News and Comments

ImmunoGen: What About Now?

  Friday, April 28, 2017

ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the promises of its novel antibody-drug conjugate (ADC). An ADC drug is an antibody that carries highly potent cancer-killing agent attached to the antibody by a linker. The linker is designed to release an exceptionally toxic agent only as the ADC reaches the cancer cells in order not to harm or kill healthy cells. Our enthusiasm for ADC products emanates from their potency compared to other antibodies and to their safety and potency compared to chemotherapy drugs. The dosage of the toxic agent in the monoclonal antibody conjugate is several times that of chemotherapy, hence the superior potency and tolerability expected from the ADC products.        More...

Companies Targeted for Takeover Yet Can Thrive on their Own

  Thursday, February 02, 2017

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unreservedly changed. What seems now to have become the best treatment choices are those that would accommodate the new wave of extremely promising immunotherapy approaches.     More...

Nektar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...

Two Small Great Biotechs Underestimated by the Market

  Tuesday, June 25, 2013

Seattle Genetics’ (SGEN) and ImmunoGen’s (IMGN) conjugated monoclonal antibody therapeutics for cancer are increasingly validating their superior safety and efficacy over other cancer products that are used without the antibody drug conjugates (ADC).  More...

ImmunoGen Offers New Hopes For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Difficult-To-Treat Cancers

  Friday, April 12, 2013


Circumstances That Encourage Picking Specific Biotech Stocks

  Tuesday, January 10, 2012

Picking biotech stocks for short-term and long-term investment could be a good practice if investors know what to pick. In most cases, picking biotech stocks that have no near-term catalysts could be disappointing, leading investors to wait and wait, then get bored, and sell their shares at a great loss. To pick firms in early- or mid-phase development the firms should have very advanced technologies and product pipelines with strong evidence of promise that they are the envy of rich pharmaceutical firms. The large-pocketed drug developers usually desire what they need and buy what they desire. Most are currently in dire need of breakthrough products, as the patent lives of many of their bestsellers are expiring. Investors must be aware of the fact that stocks of development-stage firms’ are destined to fall after each and every quarterly financial results announcement, as they have no revenues or incomes. They also fall after shareholders get disappointed in the negative performances of their stocks, hence, trash them. Compensation can come early, however, in the event of takeovers, alliances that pay huge upfront payments, or the announcement of stunningly positive clinical trial results of products that deal with life-threatening diseases with large markets. Focused investors may be able to catch big fish in situations exemplified by the following three circumstances: More...

Seattle Genetics: Bearish vs. Bullish opinions

  Monday, October 10, 2011

As much as it is vexing when analysts downgrade stocks without bothering explaining the reasons for their decisions, it is refreshing when analysts or investors explain the reasons that led them to bet against some firms. Our eyes have finally fallen on a couple of articles citing the reasoning that motivates short analysts to bet against stocks many other investors believe they offer excellent investment opportunities. These authors offer an opportunity for positive investors to dispute their views, while stressing their own.     More...

Seattle Genetics: A powerful Approach For resistant Cancers Hits The Market

  Tuesday, August 23, 2011

We heard them all. We heard all they said, we mean the pessimist and the optimist following the approval of Seattle Genetics’ drug Adcentris™ (brentuximab vedotin) for Hodgkin lymphoma and for systemic anaplastic large cell lymphoma (ALCL). More...

Seattle Genetics: Adcentris Approved For Two Cancers

  Monday, August 22, 2011

Congratulations. A great technology, the antibody-drug conjugate (ADC) technology, which is perfected by the two biotech firms, Seattle Genetics (SGEN) and ImmunoGen (IMGN) has yielded the first approved drug. Yes, the FDA has granted accelerated approval of Adcentris™ (brentuximab vedotin) developed by Seattle Genetics (SGEN) for two indications:  More...

Gilead, Dendreon, Seattle Genetics And Great News For CLL Patients. Who Confused Investors?

  Friday, August 12, 2011

It was crazy. During the market’s dive, Gilead’s (GILD) stock was oversold. The stock experienced a selloff after having been snubbed for years never mind it has contributed to turning a killer virus into a tamed manageable disease, or that its revenues and incomes have exceeded Wall Street exaggerated expectations.      More...

Recent Postings



Ridaforolimus Abbott Laboratories (ABT) Auspex (ASPX) Benlysta (belimumab) ADVENTRIX (ANX) AstraZeneca (AZN) Theravance Bio Pharma (TBPH) Spike Therapeutics (ONCE) Sanofi (SNY) NOVOCURE (NVCR) Dynavax (DVAX) ZALTRAP™ LEXICON (LXRX) NANTKWEST (NK) Epizyme (EPZM) Sangamo (SGMO) Galena (GALE) Akebia Therapeutics (AKAB) MODERNA OSI (OSIP) Array Pharmaceuticals (ARRY) Rapamune ARGOS (ARGS) BIOMARIN (BMRN) GlaxoSmithKline (GSK) Intrexon (XON) Zerenex SERES THERAPEUTICS (MCRB) Micromet (MITI) GlycoMimetics (GLYN) Sarepta (SRPT) Human Longevity (HLI) Cytokinetics (CYTK) Anadys (ANDS) Onyx (ONXX) Amgen (AMGN) Telaprevir CEMPRA (CEMP) Alnylam (ALNY) Advaxis (ADXS) Roche (RHHBY) Jazz Pharmaceuticals (JAZZ) Agenus (AGEN Incyte (INCY) NEUROCRINE (NBIX) Alder Biopharmaceuticals (ALDR) REGULUS (RGLS) TOKAI (TKAOI) JOUNCE THERAPEUTICS (JNCE) Intercept (ICPT) Intermune (ITMN) Ariad (ARIA) Biocryst (BCRX) PORTOLA (PTLA) Merck (MRK) Valeant Pharmaceuticals International (VRX) GUARDIAN HEALTH Sequenom (SQNM) JUNO (JUNO) Seattle Genetics (SGEN) IDERA (IDRA) Xoma (XOMA) Tysabri SUNESIS PHARMACEUTICALS (SNSS) KITE (KITE) AERIE PHARMACEUTICALS Anacor (ANAC) Roche (ROCHE) Prosensa (RNA) RenenxBio (RGNX) Global Cell Therapeutics (GBT) Idenix (IDIX) Pluristem (PSTI) Regeneron (REGN) Aimmune Therapeutics (AIMT) Editas (EDIT) INNOVIVA (INVA) Vitae Pharmaceuticals (VTAE) Agenus (AGEN) SYNTA (SNTA) Human Genome Sciences (HGSI) Vertex (VRTX) Bellicum (BLCM) Bristol-Myers Squibb (BMY) Trastuzumab-DM1 Herceptin Inovio (INO) Endometrial Cancer ISIS (ISIS) Ziofpharm (ZIOP) CRISPR Therapeutics (CRSP) VANDA (VNDA) Gilead (GILD) OncoCyte (OCX) Theravance (THRX) Genentech Elan (ELN) Prolor Biotech (PBTH) ABBVIE (ABBV) Multiple Myeloma Ocular Therapeutix (OCUL) Sanofi-Aventis (SAN) ImmunoGen (IMGN) AGOS (ARGS) Revlimid (lenolidamide) Sanofi (SNA) ACADIA (ACAD) Ionis (IONS) NEKTAR (NKTR)) CompuGen (CGEN) Exelixis (EXEL) Adaptimmune (ADAP) Biogen Idec (BIIB) Mirati Therapeutics (MRTX) C4 Therapeutics Velcade (bortezomib) Dendreon (DNDN) galapagos (GLPG) Illumina (ILMN) ARCA (ABIO) HALOZYME (HALO) KERYX (KERX) PTC Therapeutics (PTCT)